Impact of pharmacotherapies for achondroplasia – Discussion 4 / 4

touchMDT for touchENDOCRINOLOGY Listen to experts Prof. Karin Blakemore, Prof. Klaus Mohnike, Prof. Janet Legare and patient advocate Carly Kutner provide their insights on the impact of pharmacotherapies for achondroplasia The multidisciplinary team and patient advocate: MFM specialist - Prof. Karin Blakemore Johns Hopkins University School of Medicine, Baltimore, MD, USA Paediatric endocrinologist - Prof. Dr. med. Klaus Mohnike  Otto-von-Guericke University Magdeburg, Magdeburg, Germany   Paediatrician - Prof. Janet Legare University of Wisconsin School of Medicine and Public Health, Madison, WI, USA Patient advocate - Ms Carly Kutner Freehold, NJ, USA This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from BioMarin Pharmaceutical Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchendocrinologyime.org/mdt-diagnosis-monitoring-early-treatment-in- achondroplasia/